You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金斯瑞生物科技(01548.HK)爲首批國產mRNA疫苗提供獨家生產服務
阿思達克 10-22 16:40
金斯瑞生物科技(01548.HK)公佈,公司非全資附屬「金斯瑞蓬勃生物」與蘇州艾博生物科技及玉溪沃森生物技術,連同金斯瑞蓬勃生物及艾博稱就mRNA疫苗的生物製品許可申請(BLA)及其商業化生產簽訂總服務協議。沃森將成爲項目的申報主體,而金斯瑞蓬勃生物將成爲項目質粒商業化生產的獨家服務供應商。 去年6月,由艾博、沃森和一家中國醫療機構聯合開發的COVID-19 mRNA疫苗已獲得國家藥品監督管理局臨牀試驗批準,該項目是國家首批立項的mRNA疫苗項目。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account